February 1, 2018 04:55 PM EST

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

Brittany Meiling

Facing a likely roadblock entering the European market, Puma Biotechnology $PBYI is inking a string of new deals in different regions for its cancer drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

Brittany Meiling

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Af­ter EMA flop, Puma takes Ner­l­ynx to Chi­na in new out-li­cens­ing deal

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal